Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03812562 · ClinicalTrials.gov registry record · Early Phase 1
Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection
A Early Phase 1 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT03812562: Clinical Trial Early Phase 1 study, sponsored by Northwestern University.
NCT03812562 is a Early Phase 1 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 2 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03812562, a Early Phase 1 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This early phase I trial studies how well nivolumab and yttrium-90 work in treating patients with liver cancer who are undergoing surgical resection. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radioactive drugs, such as yttrium-90, may carry radiation directly to tumor cells and not harm normal cells. Giving nivolumab and yttrium-90 may work better in treating patients with liver cancer.
Primary Outcome
This primary dichotomous endpoint will be summarized at each time point using a table of frequencies and counts.
Interventions
- BIOLOGICAL Nivolumab
- RADIATION Yttrium Y 90 Glass Microspheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-02-07 |
| Est. Completion | 2023-10-19 |
| Phase | Early Phase 1 |
Why NCT03812562 stopped before completion
NCT03812562 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03812562 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03812562 about?
NCT03812562 is a clinical study titled "Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection". This early phase I trial studies how well nivolumab and yttrium-90 work in treating patients with liver cancer who are undergoing surgical resection. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body?s immune system attack the cancer, and may interfere with the ability o...
What is the current status of trial NCT03812562?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2019-02-07. Estimated completion is 2023-10-19.
What interventions are being tested in trial NCT03812562?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Yttrium Y 90 Glass Microspheres (RADIATION).
Who is sponsoring clinical trial NCT03812562?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03812562's enrollment target sits among peer trials
2 1973rd of 2000 higher than 16 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI